Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study

BACKGROUND: Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the pharmacologically active metabolite of dimethyl fumarate (DMF). DRF 462 mg and DMF 240 mg produce bioequivalent exposure of monome...

Descripción completa

Detalles Bibliográficos
Autores principales: Naismith, Robert T., Wundes, Annette, Ziemssen, Tjalf, Jasinska, Elzbieta, Freedman, Mark S., Lembo, Anthony J., Selmaj, Krzysztof, Bidollari, Ilda, Chen, Hailu, Hanna, Jerome, Leigh-Pemberton, Richard, Lopez-Bresnahan, Maria, Lyons, Jennifer, Miller, Catherine, Rezendes, David, Wolinsky, Jerry S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018784/
https://www.ncbi.nlm.nih.gov/pubmed/31953790
http://dx.doi.org/10.1007/s40263-020-00700-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018784/
https://www.ncbi.nlm.nih.gov/pubmed/31953790
http://dx.doi.org/10.1007/s40263-020-00700-0

Ejemplares similares